PMO Interview with the Innovator Series: Volume 7
Video Categories: PMO Interview with the Innovator Series
Dixie-Lee Esseltine, MD and George Mulligan, PhD explain ixazomib’s mechanism of action and how the drug may fit into the treatment regimen for patients upon approval and beyond.
Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.